EVP & Head of Development, Biogen

Priya Singhal, M.D., M.P.H. is an accomplished physician scientist and business C-suite leader committed to developing drugs across diverse therapeutic areas that can transform the lives of patients and their caregivers. Over her drug development career, Priya has significantly contributed to more than 100 programs and led the worldwide approvals of more than 12 first in class and best in class products. Since January 2023 she is the Biogen Executive Vice President (EVP), Head of Development. Priya has accountability of the entire Biogen clinical and marketed portfolio and oversees capital allocation of a multibillion-dollar budget. Dr. Singhal rejoined Biogen in 2020 to lead Global Safety & Regulatory Sciences as well as Japan and China R&D and was promoted to Interim Head of R&D in 2021 prior to being confirmed in January 2023. She had several roles of increasing responsibility at Biogen during her prior tenure from 2012 – 2018 and made significant leadership and technical contributions to the Biogen portfolio, R&D strategy and governance as well as the filings and approvals of nine products. Prior to her return to Biogen in 2020, Dr. Singhal served as Head of R&D and Manufacturing at Zafgen Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients aWected by a range of metabolic diseases. From 2008 – 2012 she held roles of increasing seniority at Vertex Pharmaceuticals managing the Hepatitus C portfolio and served as the Vice President, Medical AWairs for the HCV and Cystic Fibrosis portfolio. She began her drug-development carer at Millennium Pharmaceuticals where she led benefit-risk for Velcade and other projects in the development portfolio. Preceding her career in the Biotechnology Industry, Dr. Singhal completed her M.P.H. in International Health at Harvard School of Public Health and obtained her training in Internal Medicine in Mumbai India. Priya is an invited speaker at Academic and Industry Forums and a guest faculty member at Harvard Medical School.